FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790210280> ?p ?o ?g. }

• W2790210280 endingPage "964" @default.
• W2790210280 startingPage "958" @default.
• W2790210280 abstract "Background: Data on temozolomide (TEM) and irinotecan (IRI) activity in recurrent Ewing sarcoma (EWS), especially in adult patients, are limited.Methods: Patients receiving TEM 100 mg/m2/day oral, and IRI 40 mg/m2/day intravenous, days 1–5, every 21 days, were included in this multi-institutional retrospective study. Disease control rate (DCR) [overall response rate (ORR) [complete response (CR) + partial response (PR)] + stable disease (SD)], 6-months progression-free survival (6-mos PFS) and 1-year overall survival (OS) were assessed.Results: The median age of the 51 patients was 21 years (range 3–65 years): 34 patients (66%) were adults (≥18 years of age), 24 (48%) had ECOG 1 and 35 (69%) were presented with multiple site recurrence. TEMIRI was used at first relapse/progression in 13 (25%) patients, while the remainder received TEMIRI for second or greater relapse/progression. Fourteen (27%) patients had received prior myeloablative therapy with busulfan and melphalan. We observed five (10%) CR, 12 (24%) PR and 19 (37%) SD, with a DCR of 71%. 6-mos PFS was 49% (95% CI 35–63) and it was significantly influenced by ECOG (6-mos PFS 64% [95% CI 45–83] for ECOG 0, 34% [95% CI 14–54] for ECOG ≥1; p = .006) and LDH (6-mos PFS 62% [95% CI 44–79] for normal LDH, 22% [95% CI 3–42] for high LDH; p = .02), with no difference according to line of treatment, age and metastatic pattern. One-year OS was 55% (95% CI 39–70), with RECIST response (p = .001) and ECOG (p = .0002) independently associated with outcome. Grade 3 and 4 toxicity included neutropenia in 12% of patients, thrombocytopenia in 4%, diarrhea in 4%.Conclusions: This series confirms the activity of TEMIRI in both adults and pediatric patients. This schedule offers a 71% DCR, independently of the line of chemotherapy. Predictive factors of response are ECOG and LDH." @default.
• W2790210280 created "2018-03-29" @default.
• W2790210280 creator A5003857662 @default.
• W2790210280 creator A5006719017 @default.
• W2790210280 creator A5015636061 @default.
• W2790210280 creator A5029663862 @default.
• W2790210280 creator A5030668768 @default.
• W2790210280 creator A5036969722 @default.
• W2790210280 creator A5047205597 @default.
• W2790210280 creator A5048969933 @default.
• W2790210280 creator A5049179597 @default.
• W2790210280 creator A5050031420 @default.
• W2790210280 creator A5050932223 @default.
• W2790210280 creator A5052085580 @default.
• W2790210280 creator A5058819069 @default.
• W2790210280 creator A5073707704 @default.
• W2790210280 creator A5080548972 @default.
• W2790210280 creator A5080940092 @default.
• W2790210280 creator A5083948167 @default.
• W2790210280 date "2018-03-13" @default.
• W2790210280 modified "2023-10-17" @default.
• W2790210280 title "Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients" @default.
• W2790210280 cites W1505048261 @default.
• W2790210280 cites W1895063114 @default.
• W2790210280 cites W1935226228 @default.
• W2790210280 cites W1968221927 @default.
• W2790210280 cites W1975044418 @default.
• W2790210280 cites W1999434056 @default.
• W2790210280 cites W2004504668 @default.
• W2790210280 cites W2011909208 @default.
• W2790210280 cites W2019607817 @default.
• W2790210280 cites W2032117049 @default.
• W2790210280 cites W2034600493 @default.
• W2790210280 cites W2042936828 @default.
• W2790210280 cites W2050049307 @default.
• W2790210280 cites W2050780415 @default.
• W2790210280 cites W2054844095 @default.
• W2790210280 cites W2062845584 @default.
• W2790210280 cites W2067019974 @default.
• W2790210280 cites W2071919091 @default.
• W2790210280 cites W2072315137 @default.
• W2790210280 cites W2090650007 @default.
• W2790210280 cites W2090853314 @default.
• W2790210280 cites W2102461238 @default.
• W2790210280 cites W2103336131 @default.
• W2790210280 cites W2103758698 @default.
• W2790210280 cites W2105687233 @default.
• W2790210280 cites W2107172831 @default.
• W2790210280 cites W2109614376 @default.
• W2790210280 cites W2118541332 @default.
• W2790210280 cites W2120332010 @default.
• W2790210280 cites W2127054479 @default.
• W2790210280 cites W2129148702 @default.
• W2790210280 cites W2149894615 @default.
• W2790210280 cites W2153544919 @default.
• W2790210280 cites W2163261709 @default.
• W2790210280 doi "https://doi.org/10.1080/0284186x.2018.1449250" @default.
• W2790210280 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29533113" @default.
• W2790210280 hasPublicationYear "2018" @default.
• W2790210280 type Work @default.
• W2790210280 sameAs 2790210280 @default.
• W2790210280 citedByCount "39" @default.
• W2790210280 countsByYear W27902102802018 @default.
• W2790210280 countsByYear W27902102802019 @default.
• W2790210280 countsByYear W27902102802020 @default.
• W2790210280 countsByYear W27902102802021 @default.
• W2790210280 countsByYear W27902102802022 @default.
• W2790210280 countsByYear W27902102802023 @default.
• W2790210280 crossrefType "journal-article" @default.
• W2790210280 hasAuthorship W2790210280A5003857662 @default.
• W2790210280 hasAuthorship W2790210280A5006719017 @default.
• W2790210280 hasAuthorship W2790210280A5015636061 @default.
• W2790210280 hasAuthorship W2790210280A5029663862 @default.
• W2790210280 hasAuthorship W2790210280A5030668768 @default.
• W2790210280 hasAuthorship W2790210280A5036969722 @default.
• W2790210280 hasAuthorship W2790210280A5047205597 @default.
• W2790210280 hasAuthorship W2790210280A5048969933 @default.
• W2790210280 hasAuthorship W2790210280A5049179597 @default.
• W2790210280 hasAuthorship W2790210280A5050031420 @default.
• W2790210280 hasAuthorship W2790210280A5050932223 @default.
• W2790210280 hasAuthorship W2790210280A5052085580 @default.
• W2790210280 hasAuthorship W2790210280A5058819069 @default.
• W2790210280 hasAuthorship W2790210280A5073707704 @default.
• W2790210280 hasAuthorship W2790210280A5080548972 @default.
• W2790210280 hasAuthorship W2790210280A5080940092 @default.
• W2790210280 hasAuthorship W2790210280A5083948167 @default.
• W2790210280 hasBestOaLocation W27902102801 @default.
• W2790210280 hasConcept C121608353 @default.
• W2790210280 hasConcept C126322002 @default.
• W2790210280 hasConcept C141071460 @default.
• W2790210280 hasConcept C142724271 @default.
• W2790210280 hasConcept C2776694085 @default.
• W2790210280 hasConcept C2777389519 @default.
• W2790210280 hasConcept C2778256501 @default.
• W2790210280 hasConcept C2778684742 @default.
• W2790210280 hasConcept C2778822529 @default.
• W2790210280 hasConcept C2780259306 @default.
• W2790210280 hasConcept C2780739268 @default.

• next